{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:09:12Z","timestamp":1791482952573,"version":"4.3.4"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"Importance<\/jats:title>EGFR<\/jats:italic>-variant non\u2013small cell lung cancer (NSCLC) is associated with a high rate of central nervous system (CNS) metastases, even with treatment with first-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate CNS activity with lazertinib, a third-generation EGFR TKI.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter single-arm, phase 2 nonrandomized controlled trial was conducted in South Korea and included patients with EGFR<\/jats:italic>-variant NSCLC who had asymptomatic or mildly symptomatic brain metastases after unsuccessful treatment with first-generation or second-generation EGFR TKIs. Data were collected from June 2021 to April 2022, with a data cutoff date of December 15, 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Lazertinib, 240 mg, once daily.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was intracranial objective response rate (iORR) in the evaluable population according to the Response Evaluation Criteria in Solid Tumours version 1.1 assessed by the investigators. Secondary end points included intracranial progression-free survival (iPFS) and iORR in patients with T790M-negative disease and isolated CNS progression as well as overall ORR, duration of response, intracranial duration of response, disease control rate, overall survival, cerebrospinal fluid penetration of lazertinib, and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 40 included patients, 25 (63%) were women, and the median (range) age was 63 (29-85) years. A total of 38 patients were evaluable for tumor response, including 12 patients with leptomeningeal metastases. At data cutoff, the median (range) follow-up was 13.6 (2.9-17.7) months. The iORR for the evaluable population was 55% (21 of 38; 95% CI, 38.3-71.4); for patients with T790M-positive disease, 80% (4 of 5; 95% CI, 28.4-99.5); for patients with T790M-negative disease, 43% (9 of 21; 95% CI, 21.8-66.0); and for patients with T790M-unknown disease, 67% (8 of 12; 95% CI, 34.9-90.1). The median iPFS was 15.8 months (95% CI, 15.2-not reached) for the evaluable population, 15.2 months (95% CI, 4.2-not reached) for the T790M-positive subgroup, 15.4 months (95% CI, 7.9-not reached) for the T790M-negative subgroup, and 18.0 months (95% CI, 3.9-not reached) for the T790M-unknown subgroup. The cerebrospinal fluid penetration rate of lazertinib was 46.2% (95% CI, 10.0-49.6), providing further support for its mechanism of intracranial response. Most adverse events were grade 1 or 2.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study, lazertinib had substantial CNS activity, regardless of T790M status, against the progression of intracranial metastases with or without leptomeningeal metastases after unsuccessful treatment with first-generation or second-generation EGFR TKIs in patients with metastatic EGFR<\/jats:italic>-variant NSCLC. These results suggest that using lazertinib instead of brain local treatment could be a potential strategy in patients with EGFR<\/jats:italic>-variant NSCLC whose CNS metastases progressed after prior EGFR TKI treatment.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05326425<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.2640","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:01:23Z","timestamp":1723734083000},"page":"1342","source":"Crossref","is-referenced-by-count":27,"title":["Lazertinib in EGFR<\/i>-Variant Non\u2013Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors"],"prefix":"10.1001","volume":"10","author":[{"given":"Min Hee","family":"Hong","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Ji","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Kyung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghwan","family":"Youk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinwon","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Department of Medicine, Physician-Scientist Program, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Systems Informatics and Graduate School of Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyoung","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary\u2019s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi240038r1","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC.","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"coi240038r2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"coi240038r3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer.","author":"Reungwetwattana","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi240038r4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"5","key":"coi240038r5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases.","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"coi240038r6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cllc.2017.10.003","article-title":"Effect of brain metastasis on patient-reported outcomes in advanced NSCLC treated in real-world community oncology settings.","volume":"19","author":"Walker","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"coi240038r7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ctrv.2018.10.011","article-title":"Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.","volume":"71","author":"Wrona","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"coi240038r8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"coi240038r9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.","volume":"29","author":"Goss","year":"2018","journal-title":"Ann Oncol"},{"issue":"15","key":"coi240038r10","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.3390\/cancers13153681","article-title":"Analyses of CNS response to osimertinib in patients with T790M-positive advanced NSCLC from ASTRIS Korean subset, open-label real-world study.","volume":"13","author":"Ahn","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"coi240038r11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40265-021-01533-x","article-title":"Lazertinib: first approval.","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"issue":"8","key":"coi240038r12","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1158\/1078-0432.CCR-18-2906","article-title":"YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer.","volume":"25","author":"Yun","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"26","key":"coi240038r13","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301.","volume":"41","author":"Cho","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi240038r14","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.jtho.2023.08.017","article-title":"Central nervous system outcomes of lazertinib versus gefitinib in EGFR-mutated advanced NSCLC: a LASER301 subset analysis.","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"coi240038r15","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaoncol.2018.0275","article-title":"Evaluating treatment effect based on duration of response for a comparative oncology study.","volume":"4","author":"Huang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"15","key":"coi240038r16","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1002\/cncr.28723","article-title":"Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.","volume":"120","author":"Sacher","year":"2014","journal-title":"Cancer"},{"issue":"11","key":"coi240038r17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI.","volume":"10","author":"Hata","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"7","key":"coi240038r18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"coi240038r19","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3).","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"coi240038r20","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.21037\/jtd.2019.05.41","article-title":"Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.","volume":"11","author":"Arulananda","year":"2019","journal-title":"J Thorac Dis"},{"issue":"12","key":"coi240038r21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1080\/0284186X.2021.1973092","article-title":"Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.","volume":"60","author":"Eide","year":"2021","journal-title":"Acta Oncol"},{"key":"coi240038r22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863666","article-title":"Efficacy of osimertinib in EGFR-mutated advanced non-small-cell lung cancer with different T790M status following resistance to prior EGFR-TKIs: a systematic review and meta-analysis.","volume":"12","author":"Yi","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"coi240038r23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors.","volume":"17","author":"Cho","year":"2022","journal-title":"J Thorac Oncol"},{"key":"coi240038r24","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000507","article-title":"How we treat patients with leptomeningeal metastases.","volume":"4","author":"Le Rhun","year":"2019","journal-title":"ESMO Open"},{"issue":"4","key":"coi240038r25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis.","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"4","key":"coi240038r26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis.","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"coi240038r27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi240038r28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1200\/JCO.2016.69.7144","article-title":"Management of brain metastases in tyrosine kinase inhibitor-na\u00efve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis.","volume":"35","author":"Magnuson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi240038r29","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.21873\/anticanres.11806","article-title":"Cerebrospinal fluid penetration rate and efficacy of afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study.","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res"},{"issue":"6","key":"coi240038r30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study.","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi240038r31","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3349\/ymj.2019.60.6.525","article-title":"Real-world analysis of the efficacy of rebiopsy and EGFR mutation test of tissue and plasma samples in drug-resistant non-small cell lung cancer.","volume":"60","author":"Hong","year":"2019","journal-title":"Yonsei Med J"},{"issue":"8","key":"coi240038r32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer.","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"coi240038r33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"coi240038r34","doi-asserted-by":"publisher","first-page":"S1306","DOI":"10.1016\/j.annonc.2023.10.062","article-title":"LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial.","volume":"34","author":"Cho","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"coi240038r35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2822323\/jamaoncology_hong_2024_oi_240038_1728488939.7989.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T15:18:52Z","timestamp":1729178332000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2822323"}},"subtitle":["A Nonrandomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.2640","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}